General recommendation for assessment and management on the risk of glucocorticoid-induced osteonecrosis in patients with COVID-19

• DOI: 10.1016/j.jot.2021.09.005
• Publication Date: 2021-10-22T07:34:53Z
• Authors: Wenlong Li; Zeqing Huang; Biao Tan; Gang Chen; Xugui Li; Kan Xiong; Ruizheng Zhu; Ruihan Li; Shuwen Li; Hengli Ye; Zhi Liang; Xiaojun Dong; Shijing Zhou; Song Chen; Haixiang Xi; Hao Cheng; Rongpeng Xu; Shenghao Tu; Zhe Chen; Lihua Qi; Jiandong Song; Ruoran Xiao; Huilan Liu; Qian Nan; Huiyong Yu; Hongsheng Cui; Yanguang Shen; Chengxiang Wang; Na Lin; Yanqiong Zhang; Weiheng Chen
• Keywords: Disease prevention and control; 0301 basic medicine; 03 medical and health sciences; 0302 clinical medicine; Coronavirus disease 2019; Severe acute respiratory syndrome; RC925-935; Osteonecrosis; Original Article; Diseases of the musculoskeletal system; Glucocorticoids; 3. Good health

Coronavirus disease 2019 (COVID-19) is a disaster in human medical history and glucocorticoids remain the most promising therapy. Osteonecrosis is a disease caused by reduced intraosseous blood flow to bones in the joints, which will rapidly induce joint destruction. Approximately one-third patients with severe acute respiratory syndrome (SARS) who received high cumulative doses and long treatment durations of glucocorticoids occurred osteonecrosis. Considering the similarity of SARS and COVID-19 on their pathogen, clinical characteristics, and therapeutic strategies, it is particularly desirable to investigate whether osteonecrosis will become a common sequela among convalescent COVID-19 patients.This multi-strategy study was designed by integrating different research methods, such as meta-analysis, systematic review, and cross-sectional investigations to address above study objectives. At first, two meta-analyses were performed on the osteonecrosis incidence among SARS patients and the clinical data of glucocorticoid exposure among COVID-19 patients. Then, a systematic review of low-dosage glucocorticoid associated osteonecrosis and a cross-sectional investigation of glucocorticoid exposure of COVID-19 patients in Wuhan city of China were also conducted. Moreover, the pathogenesis, diagnosis, prevention, and treatment options for osteonecrosis patients with COVID-19 infection were further presented and discussed.Our meta-analysis showed that 32% of SARS patients had developed osteonecrosis after receiving glucocorticoid treatment with high dose, and our system review supported that low level glucocorticoid exposure might also lead to the occurrence of osteonecrosis. Similarly, 40% of COVID-19 patients had undergone glucocorticoid treatment according to our meta-analysis. The cross-sectional investigation in Wuhan city of China found that the average of cumulative glucocorticoid exposure level was 504 ​mg calculated by the dosage of methylprednisolone. Notably, a confirmed osteonecrosis case was identified from 1406 patients with COVID-19 during our cross-sectional investigation, implying that preventive management of osteonecrosis should be better started with regular clinical follow-up observation.Growing evidence of the glucocorticoid therapy for COVID-19 patients prompts us to establish risk-classification-based early screening and to introduce early prevention protocol of its associated osteonecrosis that will be of clinical significance in favor of improved prognosis of this disease.To establish risk-classification-based early screening and to introduce early prevention protocol of glucocorticoid-induced osteonecrosis will be of clinical significance in favor of improved prognosis of COVID-19.